Xintela and NorthX Biologics sign framework agreement for collaboration

Xintela and NorthX Biologics announce that they have signed a collaborative framework agreement to jointly accelerate the development of advanced therapeutics (ATMP) by leveraging the companies’ complementary skills and resources in ATMP development and GMP manufacturing. Projects to be initiated within the framework of the collaboration include, among other things, product and process development, quality control and increased expansion capacity for manufacturing ATMPs.

“This is a very interesting opportunity for us. Xintela has developed the unique stem cell product XSTEM, which is now in clinical development, and has strong expertise in process development and GMP manufacturing of stem cells and other ATMPs. Together with NorthX Biologics and their manufacturing capacity, we can further expand and also broaden our ATMP business”, says Evy Lundgren-Åkerlund, CEO of Xintela.
“This collaboration is another step in the right direction towards becoming a leading solution provider in the cell and gene therapy space, adding to the solid expertise NorthX has already gained from +30 years of advanced biological GMP manufacturing. I am happy to work with Xintela and look forward to our relationship going forward,” says Helena Strigård, CEO of NorthX Biologics.

Xintela and NorthX Biologics sign framework agreement for collaboration
Xintela and NorthX Biologics sign framework agreement for collaboration

About NorthX Biologics AB

NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.

For more news, follow us on

LinkedIn